Table 2.
Serostability for BK and JC human polyomavirus (PyV) seropositivitya in samples collected longitudinally over time among 210b controls from the Skin Cancer Prevention Study.
| PyV | Controls Serostability (n=210), No. (%) | ||||
|---|---|---|---|---|---|
| Stably seropositive | Stably seronegative | Seroconversion | Seroreversion | Fluctuating | |
| BK | 201 (95.7) | 6 (2.9) | 2 (0.9) | None | 1 (0.5) |
| JC | 157 (74.8) | 44 (20.9) | 6 (2.9) | 2 (0.9) | 1 (0.5) |
a
PyV infection was determined using seropositivity for the VP1 protein.
b
Not including 19 controls who only had a single sample collected. Only controls with ≥2 repeated serum samples were included.